Author(s):
Gurram Lakshmana murthy, Vasia Tamreen, Chandrika C., Shazia Iryn, Suchitra M, Balireddy N, Nagaraja Sreeharsha, Shaik Sadik
Email(s):
murthympharm@gmail.com
DOI:
10.52711/0974-360X.2021.00487 
Address:
Gurram Lakshmana murthy1, Vasia Tamreen1, Chandrika C.2, Shazia Iryn1, Suchitra M3, Balireddy N4, Nagaraja Sreeharsha5,6, Shaik Sadik7
1Department of Pharmaceutics, Oxbridge College of Pharmacy, Bengaluru-91, Karnataka, India.
2Department of Pharmacy Practice, Oxbridge college of Pharmacy, Bengaluru-91, Karnataka, India.
4Department of Pharmaceutical Chemistry, Bapuji college of Pharmacy, Davanagere, Karnataka, India.
4Department of Pharmaceutical chemistry, Oxbridge college of Pharmacy, Bengaluru-91, Karnataka, India.
5Department of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University,
Al Ahsa-31982, Saudi Arabia.
6Department of Pharmaceutics, Vidyasiri College of Pharmacy, Off Sarjapura Road, Bengaluru-560035, Karnataka, India.
7Department of Pharmacology, Oxbridge college of Pharmacy, Bengaluru-91, Karnataka, India.
*Corresponding Author
Published In:
Volume - 14,
Issue - 5,
Year - 2021
ABSTRACT:
The main of the research work to develop sustained release floating matrix tablets of ATZ, which were designed to extend the gastric residence time and prolong the drug release after oral administration. Different grades of polymers such as EC and HPMC K100M were used in order to get the desired floating and sustained release profile over prolonged period of time. All the formulations extended the drug release up to 24 hours and more and the formulations were optimized for the desired release profiles. The release and floating property was depends on the polymer type and polymer proportion. The formulation prepared with Ethyl cellulose and HPMC K100M has more floating time than the formulation prepared with the Ethyl cellulose alone. The FTIR study shows that there is no drug-polymer interaction. This study gives the preliminary idea about the development of the floating drug delivery systems of Atazanavir without the use of gas generating agent.
Cite this article:
Gurram Lakshmana murthy, Vasia Tamreen, Chandrika C., Shazia Iryn, Suchitra M, Balireddy N, Nagaraja Sreeharsha, Shaik Sadik. Design and In vitro Evaluation of floating tablets Containing Atazanavir Sulphate. Research Journal of Pharmacy and Technology. 2021; 14(5):2763-0. doi: 10.52711/0974-360X.2021.00487
Cite(Electronic):
Gurram Lakshmana murthy, Vasia Tamreen, Chandrika C., Shazia Iryn, Suchitra M, Balireddy N, Nagaraja Sreeharsha, Shaik Sadik. Design and In vitro Evaluation of floating tablets Containing Atazanavir Sulphate. Research Journal of Pharmacy and Technology. 2021; 14(5):2763-0. doi: 10.52711/0974-360X.2021.00487 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2021-14-5-71
REFERENCES:
1. Bristol-Mayers Pharmaceuticals LTD, Reyataz® US prescribing information (09/08)
2. Clotilde Allevena, Clinical Medicine Therapeutics, 2009;243-252.
3. Laura Dickinson, Journal of Antimicrobial Chemotherapy (2009)63,1233-1243.
4. Ozdemir N, Ordu S, Ozkan Y. Studies of floating dosage forms of furosemide:- In vitro
5. Yang L, Eshraghi J, Fassihi R. A new intra-gastric delivery system for the treatment of H. pylori associated gastric ulcer:- In vitro evaluation. J Contr Rel 1999; 57:- 215-22.
6. Clarke GM, Newton JM, Short MB. Comparative gastrointestinal transit of pellet system of varying density. Int J Pharm 1995; 114:-1-11.
7. Shweta A, Javed A, Alka A, Roop KK, Sanjula B. Floating drug delivery systems:- a review.
8. Groning R, Heun G. Drug Dev Ind Pharm The Drug Carrier through Gastro-retentive floating drug delivery system 1984; 10:-527-539.
9. Klausner EA, Lavy E, Friedman M, Hoffman A. J Cont Rel The Drug Carrier through Gastro-retentive floating drug delivery system 2003; 90:- 143-162.
10. Fell J T, Whitehead L, Collet H. Pharm Technol Applications of Gastro-retentive Floating Drug Delivery System 2000; 24(3):- 82-90.
11. http:-//www.drugs.com/ppa/Atazanavir-sulfate.html (26/03/2011)
12. http:-//www.rxlist.com/reyataz-drug.htm (26/03/2011)
13. http://dailymed.nlm.nih.gov/dailymed/arcHIVes/fdaDrugInfo.cfm.arcHIVeid=4548(26/03/20 11).